结核治疗过程中获得性表型耐药及其补偿性进化相关的遗传因素
该回顾性病例对照研究纳入中国天津15家诊所337例肺结核患者,比较获得性异烟肼/利福平耐药组与无获得性耐药组,并对46例患者的149株纵向分离株行全基因组测序。结果显示抗结核治疗中断≥30天与获得性表型耐药相关(aOR=2.2,95%CI 1.0-5.1),MTB进化速率为每基因组每年1.2个单核苷酸多态性(95%CI 1.02-1.38)。
要点
- 抗结核治疗中断≥30天与获得性表型INH/RIF耐药相关(aOR=2.2,95%CI 1.0-5.1)。
- MTB在宿主内环境与抗结核药双重压力下进化速率为每基因组每年1.2个SNP(95%CI 1.02-1.38)。
- 获得性INH耐药16例中10例、RIF耐药22例中9例在表型耐药出现前已检出耐药相关突变。
核心结论
- 补偿性进化可能促进INH/RIF耐药突变的固定并影响表型耐药。
- 结核治疗应根据基因测序结果调整,尤其在治疗期间持续培养阳性时,这凸显WGS在表型药敏试验前识别再感染和获得性耐药中的临床重要性。
研究设计与样本
- 回顾性病例对照研究,纳入中国天津15家诊所337例肺结核患者,均有至少两个时间点的表型药敏试验结果,时间范围为2009年1月1日至2016年12月31日。
- 病例组为对异烟肼(INH)或利福平(RIF)获得性耐药者,对照组为无获得性耐药者。
- 对46例治疗期间获得或逆转表型INH/RIF耐药患者的149株纵向MTB分离株行全基因组测序(WGS)。
主要发现
- 抗结核治疗中断≥30天与获得性表型INH/RIF耐药相关(aOR=2.2,95%CI 1.0-5.1),并与新rpoB突变相关(p=0.024)。
- MTB在宿主内环境与抗结核药双重压力下的进化速率为每基因组每年1.2个单核苷酸多态性(95%CI 1.02-1.38)。
- 获得性表型INH耐药病例中16例有10例、获得性表型RIF耐药病例中22例有9例,其耐药相关突变出现在表型耐药出现之前。
临床怎么用
- 作者认为结核治疗应根据基因测序结果调整,尤其在治疗期间持续培养阳性时。
- 作者指出WGS在表型药敏试验前识别再感染和获得性耐药具有临床重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We elucidated the factors, evolution, and compensation of antimicrobial resistance (AMR) in Mycobacterium tuberculosis (MTB) isolates under dual pressure from the intra-host environment and anti-tuberculosis (anti-TB) drugs. METHODS: This retrospective case-control study included 337 patients with pulmonary tuberculosis from 15 clinics in Tianjin, China, with phenotypic drug susceptibility testing results available for at least two time points between January 1, 2009 and December 31, 2016. Patients in the case group exhibited acquired AMR to isoniazid (INH) or rifampicin (RIF), while those in the control group lacked acquired AMR. The whole-genome sequencing (WGS) was conducted on 149 serial longitudinal MTB isolates from 46 patients who acquired or reversed phenotypic INH/RIF-resistance during treatment. The genetic basis, associated factors, and intra-host evolution of acquired phenotypic INH/RIF-resistance were elucidated using a combined analysis. RESULTS: Anti-TB interruption duration of ≥30 days showed association with acquired phenotypic INH/RIF resistance (aOR = 2·2, 95% CI, 1·0-5·1) and new rpoB mutations (p = 0·024). The MTB evolution was 1·2 (95% CI, 1·02-1·38) single nucleotide polymorphisms per genome per year under dual pressure from the intra-host environment and anti-TB drugs. AMR-associated mutations occurred before phenotypic AMR appearance in cases with acquired phenotypic INH (10 of 16) and RIF (9 of 22) resistances. DISCUSSION: Compensatory evolution may promote the fixation of INH/RIF-resistance mutations and affect phenotypic AMR. The TB treatment should be adjusted based on gene sequencing results, especially in persistent culture positivity during treatment, which highlights the clinical importance of WGS in identifying reinfection and AMR acquisition before phenotypic drug susceptibility testing.
引用
- Zhang G, Sun X, Fleming J, et al. Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment. Clin Microbiol Infect. 2024. PMID: 38286176. doi:10.1016/j.cmi.2024.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。